IMMUNO-ONCOLOGY DRUGS MARKET ANALYSIS

Regional Analysis

To learn more about this report, request sample copy

North America currently dominates the global immuno-oncology drugs market with an estimated market share of 35.2% in 2024. The U.S. is a major market for immuno-oncology drugs, owing to factors such as rising disposable income, increasing prevalence of cancer, and growing acceptance of immunotherapy in recent years among patients and healthcare professionals. Moreover, robust presence of global pharmaceutical players such as Merck, Bristol-Myers Squibb, and Roche have strengthened the supply chain of IO drugs in the region.

Asia Pacific is the fastest growing region. Rapid economic development and improving standards of living have enhanced the affordability of immuno-oncology therapies in several developing countries of Asia such as China, India, South Korea and Japan. The sizable population base also presents a massive patient pool undergoing cancer treatments. Rising medical tourism and growing penetration of health supports the proliferation of IO therapies in private healthcare settings across urban regions. Local generics manufacturers have further expanded the access of low-cost IO combination therapies, while foreign drugmakers are augmenting their presence through strategic partnerships with regional biotech firms.